

14 June 2023

TruSpine Technologies plc
(**"TruSpine"** or the **"Company"**)

Directorate change

TruSpine Technologies Plc, the medical device company focused on the spinal (vertebral) stabilisation market, announces that the Company has terminated its letter of appointment agreement with Annabel Schild, Independent Non-Executive Director of the Company, with immediate effect and Ms. Schild has been removed as a director of the Company with immediate effect.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation, and the Directors of the Company are responsible for the release of this announcement.

Enquiries:

TruSpine Technologies Plc

Tel: +44 (0)20 7118 0852

Laurence Strauss, Chief Executive Officer

Cairn Financial Advisers LLP (AQSE Corporate Adviser)

Tel: +44 (0)20 7213 0880

Liam Murray / Ludovico Lazzaretti

Oberon Capital (Joint Broker)

Tel: +44 (0)20 3179 5300

Mike Seabrook / Chris Crawford

Peterhouse Capital Limited (Joint Broker & Financial Adviser)

Tel: +44 (0)20 7469 0930

Lucy Williams / Duncan Vasey

Novus Communications (PR and IR)

Tel: +44 (0)20 7448 9839

Alan Green / Jacqueline Briscoe

novuscomms@truspine.org